Nuvation Bio: Hidden Valuation Reserves in the Precision Oncology Sector?
Reading Time: 3 minutes
Nuvation Bio (NUVB) looks at a strong Q2 and liquidity of USD 661 million. JPMorgan initiated coverage on August 18, 2026, with an "Overweight" rating and a price target of USD 13, driven by solid first-line acceptance. Additional revenue potential arises from prevalence-driven gene sequencing and the pipeline surrounding the drug Safusidenib. Focus on targeted cancer therapies and strengthened capital base Nuvation Bio's (NUVB) business model focuses on targeted cancer therapies to address genetic mutations in oncology. The growth driver is...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
